| Bioactivity | Liraglutide-d8 (triTFA) is the deuterium labeled Liraglutide (HY-P0014)[1]. |
| Invitro | 氢、碳和其他元素的稳定重同位素已被纳入药物分子中，主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注，因为它可能影响药物的药代动力学和代谢谱[1]。 |
| Name | Liraglutide-d8 (triTFA) |
| Shortening | HAEGTFTS-{Asp-d8}-VSSYL-{N6-[N-(1-oxohexadecyl)-L-γ-Etamyl]-Glu}-GQAAKEFIAWLVRGRG (TFA salt) |
| Formula | C178H260D8F9N43O57 |
| Molar Mass | 4098.98 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-226. |